Meeting
2021 ASCO Annual Meeting
Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.
Authors
Eliza Anne Hawkes
Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
Eliza Anne Hawkes , Sze Ting Lee , Geoff Chong , Michael Gilbertson , Andrew Grigg , Leonid Churilov , Tineke Fancourt , Colm Keane , David Ritchie , Rachel Koldej , Rishu Agarwal , Kate Manos , Charmaine Smith , Kristen Houdyk , Joanne Hawking , Allison Barraclough
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03245021
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7560)
DOI
10.1200/JCO.2021.39.15_suppl.7560
Abstract #
7560
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.
First Author: Geoffrey Chong
Poster
2024 ASCO Annual Meeting
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.
First Author: Geoffrey Chong
Poster
2023 ASCO Annual Meeting
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
First Author: Koichi Azuma
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi